Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), today announced that Yossi Maimon, the Company's Vice President and Chief Financial Officer, will present at the Oppenheimer 23rd Annual Healthcare Conference on Wednesday, December 12, 2012 at 11:10AM EST. The conference will be held at The Waldorf-Astoria Hotel in New York City on December 12-13, 2012.

A live webcast of the presentation will be available at www.protalix.com on the event calendar page. A replay will be archived and available after the conclusion of the presentation for 30 days.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system, ProCellEx®. Protalix's unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix's first approved product manufactured by ProCellEx, ELELYSO™ (taliglucerase alfa), an enzyme replacement therapy for the treatment of Gaucher disease, was approved for marketing by the U.S. Food and Drug Administration in May 2012, and by Israel's Ministry of Health in September 2012. Additional marketing applications for taliglucerase alfa have been filed in other countries. Protalix is partnered with Pfizer Inc. for worldwide development and commercialization, excluding Israel, where Protalix retains full rights. Protalix's development pipeline also includes the following product candidates: PRX-102, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; PRX-105, a pegylated recombinant human acetylcholinesterase in development for several therapeutic and prophylactic indications, a biodefense program and an organophosphate-based pesticide treatment program; an orally-delivered glucocerebrosidase enzyme that is naturally encased in carrot cells, also for the treatment of Gaucher disease; pr-antiTNF, a similar plant cell version of etanercept (Enbrel®) for the treatment of certain immune diseases such as rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis; and others.

CONTACT: Investor Contact
         Tricia Swanson
         The Trout Group, LLC
         +1 646 378 2953
         tswanson@troutgroup.com

         Media Contact
         Kari Watson
         MacDougall Biomedical Communications
         + 1 781-235-3060
         kwatson@macbiocom.com